Search | Engineering

订阅投稿

首页工程期刊工程焦点工程成就工程前沿关于我们 English

资源类型

期刊论文 2

年份

2020 1

2013 1

关键词

检索范围：

排序：展示方式：

Therapeutic effects of thalidomide in hematologic disorders: a review

null

《医学前沿（英文）》 2013年第7卷第3期页码 290-300 doi: 10.1007/s11684-013-0277-z

摘要：

The extensive autoimmune, anti-inflammatory, and anticancer applications of thalidomide have inspired a growing number of studies and clinical trials. As an inexpensive agent with relatively low toxicity, thalidomide is regarded as a promising therapeutic candidate, especially for malignant diseases. We review its therapeutic effects in hematology, including those on multiple myeloma, Waldenstroem macroglobulinemia, lymphoma, mantle-cell lymphoma, myelodysplastic syndrome, hereditary hemorrhagic telangiectasia, and graft-versus-host disease. Most studies have shown satisfactory results, although several have reported the opposite. Aside from optimal outcomes, the toxicities and adverse effects of thalidomide should also be examined. The current work includes a discussion of the mechanisms through which the novel biological effects of thalidomide occur, although more studies should be devoted to this aspect. With appropriate safeguards, thalidomide may benefit patients suffering from a broad variety of disorders, particularly refractory and resistant diseases.

关键词： thalidomide multiple myeloma lymphoma

HTML PDF 收藏

Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence

Huanping Wang, Haitao Meng, Jinghan Wang, Yinjun Lou, Yile Zhou, Peipei Lin, Fenglin Li, Lin Liu, Huan Xu, Min Yang, Jie Jin

《医学前沿（英文）》 2020年第14卷第3期页码 327-334 doi: 10.1007/s11684-019-0712-x

摘要： This study aimed to investigate the prevalence, clinical characteristics, and prognostic impact of 1p32.3 deletion in patients with newly diagnosed multiple myeloma (MM). A retrospective analysis was conducted on 411 patients with newly diagnosed MM; among which, 270 received bortezomib-based therapies, and 141 received thalidomide-based therapies. Fluorescence hybridization (FISH) was performed to detect six cytogenetic abnormalities, namely, del(1p32.3), gain(1q21), del(17p13), del(13q14), t(4;14), and t(11;14). Results showed that 8.3% of patients with MM were detected with del(1p32.3) and had significantly more bone marrow plasma cells ( = 0.025), higher 2-microglobulin levels ( = 0.036), and higher lactate dehydrogenase levels ( = 0.042) than those without del(1p32.3). Univariate analysis showed that patients with del(1p32.3) under thalidomide-based therapies (median PFS 11.6 vs. 31.2 months, = 0.002; median OS 16.8 vs. 45.9 months, <0.001) were strongly associated with short progression-free survival (PFS) ( = 0.002) and overall survival (OS) ( <0.001). Multivariate analysis revealed that del(1p32.3) remained a powerful independent factor with worse PFS ( = 0.006) and OS ( = 0.016) for patients under thalidomide-based treatments. Patients with del(1p32.3) under bortezomib-based treatments tended to have short PFS and OS. In conclusion, del(1p32.3) is associated with short PFS and OS in patients with MM who received thalidomide- or bortezomib-based treatments.

关键词： 1p32.3 deletion 1q21 gain prognosis multiple myeloma FISH bortezomib thalidomide